Results 51 to 60 of about 3,505 (170)
Hyperactive bladder: concept of disease and paradigms in the treatment
Медицинский совет, 2021 World studies have shown that the mean prevalence of overactive bladder (OAB) ranges today from 11 to 16% of the global population and is common in both men and women. In addition, OAB is a diagnosis by exclusion.
G. G. Krivoborodov +2 more
doaj +1 more source
Neurourology and Urodynamics, Volume 45, Issue 8, Page 1476-1478, November 2026.ABSTRACT Aims To summarize current evidence on β3‐adrenoceptor agonists for managing neurogenic lower urinary tract dysfunction (NLUTD), focusing on their efficacy, safety, and clinical role in optimizing bladder storage and protecting upper tracts. Methods Evidence from randomized controlled trials, meta‐analyses, and observational studies in spinal ...
Sharon E. Fishberg, Rano Matta
wiley +1 more source
BiomedicinesLower urinary tract dysfunction is clinically important because it may cause urinary tract infections, mainly due to accumulation of residual urine, and adversely affect renal function.
Matjaž Kopač
doaj +1 more source
“What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox
Neurourology and Urodynamics, Volume 45, Issue 8, Page 1479-1481, November 2026.ABSTRACT Objectives Neurogenic lower urinary tract dysfunction (NLUTD) severely impairs patient quality of life (QoL). While oral medications are often first‐line treatments, their high failure rates and side effects limit their effectiveness. Thus, we argue for the use of intravesical botulinum toxin A (BoNT‐A) injections as a first‐line alternative ...
Vada Furlan +2 more
wiley +1 more source
Toxins, 2016 Botulinum neurotoxin (BoNT) is used to treat a variety of ailments, and its therapeutic application in lower urinary tract disorders (LUTDs) is well studied.
David C. Moore +2 more
doaj +1 more source
Neurourology and Urodynamics, Volume 45, Issue 8, Page 1493-1499, November 2026.ABSTRACT Aims Neurogenic lower urinary tract dysfunction (NLUTD) describes a wide range of symptoms depending on neurologic diagnosis and the resulting bladder and sphincter dysfunction. This narrative review is designed to address the question regarding which NLUTD population benefits most from pelvic floor therapy and behavioral interventions, and ...
Sara M. Lenherr
wiley +1 more source
URODYNAMIC BLADDER PATTERNS IN SPINAL CORD INJURY PATIENTS
Pakistan Armed Forces Medical Journal, 2017 Objective: To determine the frequency of various neurogenic bladder patterns in patients with traumatic spinal cord injury presenting at Armed Forces Institute of Rehabilitation Medicine Rawalpindi based on urodynamic studies.
Tariq Aziz +5 more
doaj +2 more sources
Neurourology and Urodynamics, Volume 45, Issue 8, Page 1500-1506, November 2026.ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang +2 more
wiley +1 more source
OnabotulinumtoxinA in the treatment of neurogenic bladder
Biologics: Targets & Therapy, 2012 Aziz Gulamhusein, Altaf MangeraDepartment of Urology Research, Sheffield Teaching Hospitals NHS Trust, Royal Hallamshire Hospital, Sheffield, United KingdomAbstract: This review examines the evidence for use of onabotulinumtoxinA in the treatment of ...
Gulamhusein A, Mangera A
doaj
Neurourology and Urodynamics, Volume 45, Issue 8, Page 1545-1555, November 2026.ABSTRACT Objective To synthesize the evidence on the efficacy and safety of mirabegron and intradetrusor onabotulinumtoxinA (BoNT‐A) as separate interventions for overactive bladder (OAB) in Parkinson's disease (PD). Methods A systematic review and meta‐analysis with parallel synthesis of two distinct interventions was conducted of randomized and ...
Hussain Arshad +4 more
wiley +1 more source